Previous 10 | Next 10 |
AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Norman LaFr...
Plus Therapeutics, Inc. (PSTV) Q2 2022 Results Conference Call July 21, 2022 05:00 PM ET Company Participants Dr. Marc Hedrick - President and Chief Executive Officer Dr. Norman LaFrance - Chief Medical Officer Andrew Sims - Chief Financial Officer Conferen...
Plus Therapeutics press release ( NASDAQ: PSTV ): Q2 GAAP EPS of -$0.24 misses by $0.02 . The Company’s cash balance was $18.1 million at June 30, 2022, compared to $18.4 million at December 31, 2021. “Clinical data from our glioblastoma and leptomeni...
Completed enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186 RNL for Leptomeningeal Metastases On track to complete key manufacturing objectives for cGMP 186 RNL to support ongoing and planned clinical trials in 2022 and beyond ...
AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will ...
Completes technology transfer and initiates cGMP manufacturing for critical Rhenium-186 NanoLiposome ( 186 RNL) drug product intermediate On track to manufacture cGMP materials to support ongoing and planned clinical trials for rare cancers in 2022 and beyond ...
Plus Therapeutics (NASDAQ:PSTV) signed a multi-year agreement to use Biocept's (NASDAQ:BIOC) cerebrospinal fluid (CSF) assay CNSide in its phase 1/2a trial called ReSPECT-LM of Rhenium-186 NanoLiposome (186RNL) to treat patients with leptomeningeal metastases (LM). LM is a ...
Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to evaluate response to treatment and treatment efficacy for patients enro...
Rhenium-186 NanoLiposome ( 186 RNL) Targeted Radiotherapeutic successfully delivered without dose limiting toxicities in initial cohort Next step: Data Safety & Monitoring Board to consider further dose escalation AUSTIN, Texas, June 16, 2022 (GLOBE NEWSWIRE) -- ...
Data validates continued high radiation absorbed of 186 RNL in escalating doses to treat glioblastoma, maintaining safety and limiting brain and whole-body exposure Company will also present at upcoming BIO International Convention 2022 being held June 13-16 in San D...
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
PLUS THERAPEUTICS Inc. Website:
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS...
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance paym...
Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announce...